实际数据显示,大多数接受lecanemab治疗的早期阿尔茨海默病患者在治疗期间持续超过2年. Most early Alzheimer’s patients on lecanemab stayed on treatment for over 2 years, real-world data shows.

超过10,000名美国患者的实验数据显示,大多数早期阿尔茨海默病患在18个月后继续接受lecanemab治疗,78. 4%的人仍在18個月後服用该药物,71. 7%的人20个月之后使用该药,而67. 3%的人24个月前开始. Real-world data from over 10,000 U.S. patients show that most early Alzheimer’s patients on lecanemab continued treatment beyond 18 months, with 78.4% still receiving it at 18 months, 71.7% at 20 months, and 67.3% at 24 months. 根据2023年1月至2025年11月的索赔数据,这些发现与临床试验结果一致,并表明尽管存在MRI监测和副作用等挑战,但仍持续使用. The findings, based on claims data from January 2023 to November 2025, align with clinical trial results and indicate sustained use despite challenges like MRI monitoring and side effects. 莱卡内马布已在53个国家获得批准,针对粉样β原纤维素,目前正在美国进行皮下自注射版本的审查,预计将于2026年5月24日作出决定. Lecanemab, approved in 53 countries, targets amyloid-beta protofibrils and is under review for a subcutaneous autoinjector version in the U.S., with a decision expected by May 24, 2026.